Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model-Reference-Cited by-同舟云学术

Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model

Published:2022-08-30 Issue:4 Volume:13 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Koszalka Paulina¹²^ORCID,George Ankita¹,Dhanasekaran Vijaykrishna³⁴,Hurt Aeron C.¹⁵⁶,Subbarao Kanta¹⁵

Affiliation:

1. WHO Collaborating Centre for Reference and Research on Influenza at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia

2. Biomedicine Discovery Institute and Department of Microbiology, Monash University, Victoria, Australia

3. School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China

4. HKU-Pasteur Research Pole, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China

5. Department of Microbiology and Immunology, University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia

6. Hoffmann-La Roche, Ltd., Basel, Switzerland

Abstract

Influenza viruses cause significant morbidity and mortality worldwide but can be treated with antiviral drugs. In 2018, a highly effective antiviral drug, baloxavir marboxil, was licensed.

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mbio.01056-22

Reference43 articles.

1. Neuraminidase Inhibitors for Influenza

2. Noshi T Yamamoto A Kawai M Yoshida R Sato A Shishido T Naito A. 2016. S-033447/S-033188 a novel small molecule inhibitor of cap-dependent endonuclease of influenza A and B virus: in vitro antiviral activity against clinical strains. Poster presentation OPTIONS IX. European Centre for Disease Prevention and Control Solna Sweden.

3. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit

4. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017–2018

5. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and effectiveness of baloxavir marboxil and oseltamivir for influenza in children: a real-world retrospective study in China;Frontiers in Pediatrics;2024-07-29

2. Real-world effectiveness and safety of Baloxavir Marboxil or Oseltamivir in outpatients with uncomplicated influenza A: an ambispective, observational, multi-center study;Frontiers in Microbiology;2024-07-23

3. The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system;Frontiers in Pharmacology;2024-07-10

4. Considerations when treating influenza infections with oseltamivir;Expert Opinion on Pharmacotherapy;2024-07-02

5. Retracted and republished from: “The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs”;mBio;2024-05-08